-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, PydOaYL2+XJv5HlCFYiowr8xxpNMZhZMydA1L3bCw4vqhfwBiD54iu9wVgqx7DVF ldGx/sbOCPLovdB+c+abNg== 0000950103-07-001829.txt : 20070720 0000950103-07-001829.hdr.sgml : 20070720 20070720105123 ACCESSION NUMBER: 0000950103-07-001829 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20070718 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20070720 DATE AS OF CHANGE: 20070720 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Shire plc CENTRAL INDEX KEY: 0000936402 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-29630 FILM NUMBER: 07990475 BUSINESS ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 ZIP: - BUSINESS PHONE: 1264333455 MAIL ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 ZIP: - FORMER COMPANY: FORMER CONFORMED NAME: SHIRE PHARMACEUTICALS GROUP PLC DATE OF NAME CHANGE: 19980302 8-K 1 dp06318e_8k.htm Unassociated Document
 


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): July 18, 2007

Shire plc

(Exact name of registrant as specified in its charter)

England and Wales

(State or other jurisdiction of incorporation)
 
 
0-29630
 
98-0484822
 
 
(Commission File Number)
    
(IRS Employer Identification No.)
 

Hampshire International Business Park, Chineham, Basingstoke,
Hampshire RG24 8EP England

(Address of principal executive offices)           (Zip code)

Registrant's telephone number, including area code      44 1256 894 000



(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 



 
Item 8.01.  Other Events
 
Shire plc has issued the press releases attached hereto as Exhibit 99.01 and Exhibit 99.02 which are incorporated by reference herein.
 
Item 9.01.  Financial Statements and Exhibits

                  (d)  Exhibits.  The following exhibits are filed herewith:

99.01                Press Release dated July 18, 2007
 
99.02                Press Release dated July 19, 2007


 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant  has duly caused  this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
  SHIRE PLC
     
     
  By: /s/ A C Russell
   
    Name: 
Angus Russell
    Title: 
Chief Financial Officer
 
Dated: July 19, 2007


 
 
EXHIBIT INDEX
 
 
Number
Description
   
99.01
Press Release dated July 18, 2007
99.02
Press Release dated July 19, 2007
 
 
 

 
 
 
EX-99.1 2 dp06318e_ex9901.htm Unassociated Document
    EXHIBIT 99.01  
       
 
Hampshire International Business Park
Chineham  Basingstoke
Hampshire RG24 8EP
United Kingdom
Tel +44 (0)1256 894000
Fax +44 (0)1256 894708
www.shire.com
 
       
 
Press Release
   
 
Second quarter 2007 results date notification - 26 July 2007

 
Basingstoke, UK and Philadelphia, US – 18 July 2007– Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) will announce second quarter 2007 earnings on Thursday 26 July 2007.

Results press release will be issued at:
12:00 BST / 07:00 EDT
Investor meeting and conference call time:
14:00 BST / 09:00 EDT

Analyst meeting and conference call:
Matthew Emmens, Chief Executive Officer and Angus Russell, Chief Financial Officer will host the investor and analyst meeting and conference call at 14:00 BST/9:00 EDT. The venue for the meeting will be at the offices of Financial Dynamics, Holborn Gate, 26 Southampton Buildings, London WC2A 1PB.

Please email claire.rowell@fd.com to register to attend the analyst meeting in London.

The details of the conference call are as follows:

UK dial in:
0800 953 0810
US dial in:
1866 789 2220
International dial in:
+44 (0) 1452 560 068
Password/Conf ID:
10176864#
Live Webcast:*
http://gaia.world-television.com/shire/20070726/

Replay:
A replay of the presentation will be available for two weeks by phone and by webcast for one year.  Details are as follows:

UK dial in
0800 953 1533
US dial in
1866 247 4222
International dial in
+44 (0) 1452 55 00 00
Pin code
10176864#

Registered in England 2883758  Registered Office as above

 
Webcast replay:*
http://gaia.world-television.com/shire/20070726/

* Email verification is required


 
For further information please contact:

Investor Relations
Souheil Salah (Rest of the World)
+44 1256 894 160
 
Heidi Wunder (North America)
+1 484 595 8970

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases.  The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions.  Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians.  Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.
 
 
 

GRAPHIC 3 logo.jpg GRAPHIC begin 644 logo.jpg M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC M+B!6,2XP,0#_VP"$``("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(" M`@("`@,#`@(#`@("`P0#`P,#!`0$`@,$!`0$!`,$!`,!`@("`@("`@("`@," M`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$! M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,` M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I M*C0U-CH.$A8:' MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7 MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1 M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6& MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76 MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`#D`K`,!$0`"$0$#$0'_V@`, M`P$``A$#$0`_`/W\H`*`"@`H`AGN+>TB::YGAMH8P2TL\B0QH`,DL[D!1CWI MI.]HIW[)?H@V\K?(^;]?_;"_9L\-7=S8:C\6O"LEW:,\=Q!IMZ-4>&1"0\3C M3Q+B0$$;>N01U%>Y2X9SRK&,HY=5C&6W.N3Y^];3_-=SFGB\-3WJQ6K6CZK? M;MU,F3]MO]E^*UENC\6?#^V%=QMXSL#_SQL4A,TO?[B&M(\*Y]S**RZHO M-V4?G*_*OO%]/A5\1O#&I^+_#'BVP;1-"N8++7IM3$ MNBSZ%>71B%M;:Q::FD$VG2RM/$(Q,B;RXVYS7D8O)LRP->EA:^%E&M73=-0M M-5$M^24+J5NO*W;J:TZU*I%RA)"))RTDTDKJJJH))8`"I((/B#3`00<$$?:.N:]!91F?3+Z]O^O4^OR(52FTFIQL]M4=OINI:?JUC; M:EI5[;:AIUW&)K2]LIH[BUN(B2!)!-$Q21,@C*DC@UQ3ISHSE3J0=.<'9QDK M.+[-/8M-6TV+M0`4`%`!0`4`%`!0`4`%`!0!B>)?$.E^$?#NN^*-7$D;SW-_.+*V:5O+\L$O)^U9;D^4\-X:-6JX M>WM"-3$35W*;;M&C%IN-WI&,%[2?6^R^=JU\1C)NG235.^R6B7=NVBMO?S[V M,'PO^RAX[U[2O[1\'^%M;^+$QMIHC<^#A%8^`M-U6*4PRV3>-M5,%OXINK1U M(G@T-)K4D@)J>X,HZ:^>X'#5'3Q>(IX!IWY:S;KN&C4G0A>5)36WM6JBOK25 MKD4\&Y*7(G5>OO134+M_S67-:VO+>_,K.R;/)/B/\"_C!\+XEU'Q]\-_$7A/ M3)9TM8M0N--G_L3[1(KO':1:K&TUL\Y5)"$-PSD*3R!7;A,UR['/EP>,I5Y1 M7PPE'G275PTE;7=HYZN'KT=9TG!;7M:/EJM-OF^NMSTS]FC]J_X@?L]>);`0 M:C?:W\/;F[@7Q%X,O+AY[7["7*SW>@B9C_9.J1)))*@A,<4[J%G5LAX^#/,@ MPF<8>490C1QD8OV59*TD]TIVMS0>SO=Q3O&VQMA<95P\HJ]Z2T<6[*W==FKW M\]GTM^K?[7GASPA=_LY?'CXO^#%TY]'^*/@'X(3)?Z6BP6VOG3?B2FHVVMW5 MLL2;[R32]?TN(3R`2E(!'(,P@#X'AO$8JGG64Y7B>95,NKX_W9.[I\^$<7"+ MN_=4JMC5'ZK7JT](U(4K-:7M4O>WI):]3\5_P!GI%'Q[^">%48^ M+'P\Q\H&,>+=)]J_2LZ;_L?-M7_N>*_&A,\3#-_6,.KNWM(=?[R/ZQZ_GT^M M"@""Z4M;7"J"S-!*JJ!DDF-@``.I)JH_%'U7Y@?RM7/[+_[0[7-PR?`SXHE& MGF92/`GB(`@R,01_Q+NA'/O7[_\`V[E'_0WPG_A32Z_]OGR7U;%1]WV%16Z* M,K?@K']$?[)?A_6_"G[./PD\/>(](U'0-] MSZ;#)QH4DXN#4=4U9KY.UCZ)KPS<*`"@`H`*`"@`H`*`"@#S/XK_`!>\`?!3 MPG=>,?B%KMOHFEP^9%9P',VI:SJ"PR31:5HUA'^\O;^41G``6.,9DGDBA1Y$ M[\NRS&9IB(X7!474GHY/:%.+=G*:<15 MVZJ_,GXH?'_4/%6D2>`/AUX>T[X4_"2TEV:?X/\.;H]4UN"*+RH;K MX@>)O^/SQAJ+R--.1=LUO&TX"Q.T"2G[C`Y5##U(XK&UI8_,-.:M4^&GWCAZ M2:A0A:R]VTY6;CLUS:[W[?T;_`CXA? M"_QW\._"_P#PJ[7-#OM(T?P]HEB^BZ7QIZ?\`E8\!937WYH1\M=/+9_F_5GVK\9_A M_P"*?A7_`,$V]=^'OC.ZTV\\1^%-$\.:;>SZ/UHV5$O`>O:IX2^$_A MB#X@WVERFTN?%=_JNQ039B:=9;&%V1FMY9XBLK?G MF4\#5\31AB,RKRP49J\:,(*55)[.;;4:;>_+:A[6(S.G1;A2CSN+U? MV5HGI;?>VZL[O72_@'A/_@JU\1+34(_^$W^&/@[6-*)<2)X8O]8\.:C"&"A' MCDU.?689]AW$QF.+?D`.G6O8Q'`&`<7]5QM:A/2WM(PJQ\[J/LFK]+/3?4YH MYO.ZYJ*M?HVG9W_%:>MGM?3]8/@E\=O`WQY\!1>._`]Q/Y,1>UUK0[\10ZSX M=U:*%9Y=*U2*&22,2^4\38SZIB4O>UIU(W]G M5@W;GA=)VO=232<6FFCUZ%:%:G&I#1=5UB^J_P"&T/SJE_X*R:1%+)$?@=J) M,?"'X,?%>3X9WFJ1?%^TUJ[@T-/%<-E)H`T9K-6274&\/ MS#43*;L8*V]OMV'AL\>3A.$98G,LTRY8]4_[,=-.?L6_:>T3?P^U7+:W\TKG M76QJHT:55T]*G12M;KV_RMYE#]G_`/X*"^'?C;XWU+PI?^`6^'^FZ/X.\0^, M]2\3:IXQMM0L;+3O#IL&O3V]AJ*0M)$+C3O#5B+:[%I*P26. M6[OK:4H<26L;'Y?4R[@&\(SS/%RI2:3]C04;QO9VE5ES1O:Z:C!I/:3.>MFL M8MQH0O9_%+1.W9)I_/\`#4^]_@C\<8?&_P"SOX8^.'Q%GT#PA!>Z3K.I^(KF M.::TT'2X=(\0:MHWG+)?W$LD<4Q4W5IH-E!+>W-E)C,9N+ MK3I2N"\*$[1]5E_`%62A/,L8J":3=*A'FG&_1U)6@I='RQG&^TFEKY]7-80D MHT8`]6TSS29;;1+G7_#]^(2. M%BO;V^U:(2*>G6X`R[DM0QF(HSMO/V=2-[K7E4:;U5_M=O.^$, MWJ*_/1COIRMQT?36_P!_7MU/TK_9S_:\^%W[1L,]AX?DN_#?C2PADN;_`,$Z M]);#4C:1&(2ZEH]S;N8M9TM7GC1Y(Q%-$Q'GV\2O&TGP^=<-X_(^6=2U?"2: M4:]--14G>T*D7K3F[-I.\9?9DVFEZF'Q=&NDH/EG_*]&OT>S\[*]K'U37SYU M!0!\T_M,_M+>%?V66 M`2R*&DD:6.&%2\A:/WLM>6.S=M_2U]3P7X)_LS^-?B!XHL_CW^UA?#Q5XTD2"^\%?#N8H_A7P M'9SJTT4=SHQC-L=2BW0%+=-\<4B--.]U=E98/8S7/L-@L/+)^'8?5L-&\:^( M2:JUI)_9GI+E>MY.TFGRQ4(74L*&'J3E&OB[2FM80Z03UU5OB6B\K;MZGW9X MN\*:-XV\*>(?!FOVPN=#\3:+J.A:G;@(K&RU.UEM)C"65A%.B2[XY`I*2(CC ME17R.&Q%7!XBABJ$N6KAYQJ0?]Z+4E?;1VLUU3:.Z45*,H->[)-->OD?S0_M M$?LE_$_]GG5;^75].EUSP&MWY>C^.].C7^SKF"8YMH]4MDD:71]1"D)(DJ^2 M74^3+(IX_<5V2G'JFM;-72=SYC$X*IAI;CEC*4&G%N+6UCZL\!?MU_M,_#^UATZU M^(-QXDTV!@R6?C*RL_$DI`&!$=6U")M3$/HBWJ@?PXKP<7PMD>,DYSP,:,WU MHN5%>O)!JG?_`+<.RGF&*IV7/S+LTG^.^VG;K:^I^A7P(_X*;^'?$]]IGAKX MT:!;>#M1O9EM1XPT)KB3PP)G7$3ZEIMP\UWI432`*9HY[M%,JEECC5G7X[-> M!*M"%2ME5:5>--7]A4LJMNJA.*C&3[1<8MI:-NR?HX?,X2:A5C[-WLFMM6DK M]M]7MI>VME]-?MZNC_LC_%MXV5T>U\&NCH0R,C?$'PD5964X92"""."#7A<( M)KB/+TU9KZPFGHTUAJQT9@T\%5:=T^2S7^.)_-+:&[6ZMOL!G6]\^(6GV9F2 MX^TEU$`@92"LQD*[2"#DCFOVZR?NNUGH[[?/R/F8I\RBM'>R^?H?NK\,?^"8 M?PJLO"6E2?$[5/$NN>,;JTBN=772=272=(TVYG7S386$$,#33"W#")YYYG\U MXVD5(E<1K^58[CK'/$3C@*5*EAHNT.>+E.2_FE[R2N[M))63LVWJ?04LJHQA M%5;RGULVEKV2[?CKY6_.7]LW]F:R_9J\?:+IV@:K>:KX0\8Z9=ZKX>;4_+.I MV$FF7$%MJNF7D\"1QW?DR7=G+'.L<1,=XJ,I:)I)/L^&<[EG6#JU*M.-+$86 M<85%&ZB^=.4)Q3UCS)23C=ZQ;NDTEYN.P?U2:<'^[EMW3ZI]^Z?R]?;_`/@E M_P"-=2TGXN>-_`JS/_8OBSX?:AK$]J3^[&L>%[ZQ6PN5&/E<6&M:M&2,;A(N M<[5QYG'.%ISRS#8NUJN%Q,(1>WN5HRYH]OBIP?R\V;Y3.4:E2%_<:V_O=+?) M2OWT/S5O/^/NZ_Z^9_\`T:U?:GDGZ!?M* M*>GOX;_TB9[&._W+"]-?_;6?!>D7.KQR76EZ+)=+/XCMHM`N+6S+";4K:YU+ M3KV/3<)\TB3:CI]@3&.',2J002#]5-4TE.:2C1;FG*UH-1E'GUT3492UZ)NQ MY5.4XWA3_P"7GNV76[T^=]NJ/U"^'W_!+#QQKNA6&K>._B'IO@O4;VT@N7\. MV.@OKUWIKSJ)/LU_?_VO:0?:HU8+(D"2HKA@LSJ`Q^%Q?'N"P]6=+"X.>)A" M32J>T5*,K:7C%TY2L]TW9V^RCU*>4S=-.4_9S=G:VU^CVU7D['@?[4WC76?` M>A^%OV0-(UZ34O"OP4DOT\1:S;P2:4GC#Q1K6I7WB1>];J<1:?I%KKD=FD M+S2AKN.YG/W81%Z^186CB:E;B.=%4\3FBBZ<&U/ZO1A&-*RERQ]^JZ;G*22] MQQBK7G?'&572A#!QEI05I/1*3WVN[6V[WOT9WG[$O[%FF?'ZQU3X@_$*^U"R M\`Z9J,NB:9IFD7"6FHZ_K%K':W%Z\]VT3M::1;PW4<9\D+---(P62);=O.Y. M)^)I9,Z>$P<(RQE6/.Y33Y*=-MJ+237-.33M?W8I:I\RM6`P,:Z=6H[4T[** M=F[+7;5:M?CW3/N3XA?\$RO@=JGA;58?A[_PD'A/Q9'8N^BWMQKVH:SIDNH0 M1$P0:I9ZI+.?LD[C;(UN\#J7W@G;L;Y3!\^HTXTY*+>KB MX):QOHFFK*VE[GH5LLH.#5)>RFOA?2][NZ[/;RZ=C\.O#VO>,/A%X^L]9TN: M\\.>,_`OB%@R+(T4UGJFCWC6]_IMWY+@36[R0SVMQ"2TFR MOOVZ^2N9WQE^+/AGX)?#S7_B%XID!LM'@"V>G)-'!=ZUJUQE-/T>P+AO])N) M1U"/Y<:2RLI2)JO+,NKYIC*6#PZUF_>E:ZIPNN:G*I M+11V6S;Z)>;/SJ_9`^&GB3]HOQ[J7[77QM9=45=5N+/X8Z!*)!IFGOIDDEM) MJ%M8O^Z_LS3W8VUFIW%KNWNKJ3,T<RO"^)FOB:G9\K MEOSU+,K+5W4(O9+HTNEM?7?U_6:OSL]4X#Q[\4_ MA[\+K?3KKQ_XKTOPK;ZM//;:;+J;S(MY/;1I+<1P^3"YW)'(C'('#"NS!Y?C M<>AP6F?M#?L]^/-1LO!^G?$'P MEXCO]?G73K/0V$T_]HSSA@MLL-S9B-V<`@!B,].]=D\FSG!0EB98.KAX4%S2 MG=+D2ZW4KHA5J$FH*I%MZ)777R.!^(O[#?[.'Q&E:\O/`EKX;U)@V=0\(RR> M'7=V))EN+73VCMKJ7<2=TT+GD^M=F"XKSK`I0CBG6IK[-9*>BTLG+WHKT:Z& M53`X:;NZ=GY-Q\ME9'P]\4?^"5TL$5UJ'PB\>23M%`TD/A[QA;Q>9<3*CL8H M=:TZ.)8%9@JJ);24\\MWKZG`M2BW9*__`#[E=OY37H<%7*4M M:,^5+I+\=5Y>6_4_(S7]`UGPIK>J^&_$.G7&D:YHE]<:;JFFW2A+BRO;60QS MP2A6925<'#*S*P(925()_0Z56G5I4ZU&:G2J14H26SC)737JCQI1E3DX27+* M+LUV9^H/A'XIZUX__P"":_QI\.Z_<&[O/AKJ_@_PWIUW([/(J35K1]K'#UXS&1E)!!X()!KZO-IRIY5F>=AE_M%!=/:05O)R2?WG]9M?SX?7GXZ?\%:(H_LGP-GV+YJW'Q`B#XPPC M:/P@Y3/]W./_0]$KW^-/\`D1/_`+"\-^54PRK^++^NDSX-O/\`C[NO^OF? M_P!&M7U9Y9^@7[2G_)G?[$_;_B3^./\`T=H]?)Y/IQ+Q3Y3PW_I$SV,=I@L+ MZ_\`MK/,OV$/"NE>+?VH_AG9:S;I=66ESZWXD2VE4-&]_P"']`U/5-)=E/!\ MG58+.X`/&;<5V<55ZF%R',)4I.$Y1A3NM+1JU80G]\)2C\SDR^$98JFI?9O) M>JU1_317X8?4'\H'[1MW/>?M`?&ZXN6+2GXL?$"/)SQ';^*M4MX%&>BK!%&H M'0!1CBOZ"R:*AE&5)*UL'AG;:S=&#:MWNW?S/DL4W]9KWTM4DODFTOP.Q^&/ MQ,_:E\+^$K72?A3J?Q+L_!T=W?S6D7AC2M4N=)^V3W+MJ#136EG)&TQNMXDP MQ(8$'!&*QQN!R.O7<\?1PLL1RQ3=64%/E2]W1R3M;;35%TJN*A!1I>T4([%-=,][J%],]Q>7<[ M"P&Z:6>1Y&/=G)[UZM/%9=0ITZ-+$X>G2HQ4(156FE&,4E&*][9))(YY4Z[D MY.G.[=_AEU^1_0-^P-'XALOV8?!&C^)=)U/1=0T/4?%FFQ6>K6%SIMY]B/B; M4[^WD:WNT23RS]N=$1HWAK MPVGC*[7:WX@N=0T^V>8`X*6FG:6X0D9!U*?UK[#@#`0A@\1CVOWF(K>P M5MXPIJ,FEYSE-7_P1.#-JCYZ=.UJ:UTTN^OW*UO.Y^R_PV\+Z9X)^'W@OPEH MT,,&F^'_``QHNEVJP*JQN+73X(Y+@[``TD\HDF=^KO*S')8U^98[$3Q6,Q6( MJ-\]:K4F[].:3=O1+1+HE8]FE%4Z=.$=%&*2MZ?J=M7*6?GO_P`%)_AMJ'C; MX`1Z_H]C->ZC\.O$UGXEN([=#).GA^XL[S2M;E6->3'!]JL;R4_PQ6$K?PU] MGP/C887-IT*DE"&-I.G&^B]K&49P7_;R4XI=92BCSLSI.6'YHJSI._\`VZU9 M[>=G\C\"O!'B[5_`'C#PQXWT!HH]9\)ZYIFOZ9YZ>9;M>:7=Q7<,=Q'QOMY& MBV2)_$CL.]?K6)P]+%8>OA:R?L:\)4YI:/EFG%V?1V=T^CU/GJ4W2J0J1WA) M.WH[V^9_1_\`"+]MKX%?$_P[9ZC=>+=-\&:_Y2KJOASQ)<"QN+.Z55$S6]RX M\FZLFD+>7*'5F7[R`U^+9CPKFV7UI0IX>6)HW]RI27-==+Q6L96W5K7ZGU%' M&4*D8VFHR_E>CO:[.T\7?M8?L_>"]'O-7U'XF>'+Q;2!YH['1[M=3U"\D524 MMK2"U#!IY"-JAW09/)%(;C4K*QD96EMK&.&"QLEG9`% M-RUI:0O*5`!D=R.#7[7EF$>7Y?@\$Y\[PU)0`=7\+?\$VOCWXJU6W-K'\0/$GA+4]$5QM>?0=(\9^ M"]+M[PCLDVHKJIC_`+T:(XX<5\MC,73J\;91A:;UP5*O&IY5*F'KS:^4/9W\ M[KH=\:3I977;7*ZC@_ESQMZ>GSZGQ%^SU_R7OX*?]E8^'G_J6Z37TF=?\B?- MO^P/%?\`IB9P8;_>/O\` MT1X2K](\/OCS+TI?G,\7./\`F'_[?_\`;3Y;_P"";'_)RA_[)IXX_P#0]$KZ M#C3_`)$3_P"PO#?E5,,J_BR_KI,^#;S_`(^[K_KYG_\`1K5]6>6?H%^TI_R9 MW^Q/_P!@?QQC_O\`:/7R>3_\E+Q3T?/AK?\`@$SV,=_N6%]?_;6.[^\L)H-`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`"OQ;`T#F,R1::]U; MR8SEX9;OP#_X)G^,-5U73=>^-US;^'_#D2K=2>%M-N1< M:WJ#AT:.TOIX_P!WI\!`<2J,R=-IY-?)9OQOA:,)T M3V:Z'H8?*Y74JSY(JSY5ONG9]M+W]3](?VJ?ACJ?B7]EWQQ\,/AEXWMPRK)DK';0R.0.?EK] M&S3B+)*^69A0HX^$JM;#5Z<(V:O.=*48KYMH\:A@L13K49.G)*$X-Z;)23?X M']$]?C!](?F?_P`%%_@A\3OC+9_">+X;^%[GQ&_A^Y\8OJRVTL47V)=1B\-K M9%_-89\TV=SC'_/(U]UP7F>`RV6/>-Q,<,JBI*'-?WK.=[6[:7]4>7F5"K5] MBJ4')1Y[VZ7Y;?>>`?L-?LQ?&[X5_',^*?'7@B]T#0?^$$\5Z4+^>:!X_M^H M-I1M(,1N3ND$$N#C^`U['%6>95C,H>'P>,C6K?6*$^2*:?+%5.9_*Z^\QR_# M5J%5N4'%=WITE_F?(5Q^P]^T_)<3R+\+]3VO-*Z_Z3:?=9V8?\M/0U]'_K/D M'_0QA]S.'ZAB?^?;^X^R?CG^S-\:_%/[,W[*_@?0?!-[>^)_`.F^+(/%>EI- M`LNE2:A+IAM%E9G"MY@@E(VD_=KYS+,[RJAGO$.*J8R-/#XJ5#V,VG::C&:E M9+LVCT<5AZL\+AZ<8-2@]4NFC1@_L3?LM_'/X8?M"^%?&'C?P+>Z%X=T_2O% M,%UJ,TUN\<,NH>'M0L[1"L;DYDN)HT&!U:M.)\]RG&Y+BL-A,9&K7G*ERP2: M>E6$I?@FS'`X2M0Q$9R@XQ2EJU;=,_<&ORD]T\'_`&A/V?O!G[1'@A_"7BE' MM+VRE>]\.>(+1$.H:%J3($::#<,26TR*J30-\LBJN>47'KY-G&)R7%*O0]ZG M+2I2;M&%A*G6%;W;75W:6 MS72_4\&IE^)I27+&ZULXO:VNO;]3S"+]G/\`:,UB:WL1\,_'UZ[2)'!%<6ER M\<9/R!@;B;9$H!QGC`->@\XRB"6XM%SF2 M/$A*BOB.(.,J\M?>[/34]+"9:Z4U4KV;CK&*V MOO=^A^P]?FQ[`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`! &0`4`?__9 ` end EX-99.2 4 dp06318e_ex9902.htm Unassociated Document
    EXHIBIT 99.02  
       
 
Hampshire International Business Park
Chineham  Basingstoke
Hampshire RG24 8EP
United Kingdom
Tel +44 (0)1256 894000
Fax +44 (0)1256 894708
www.shire.com
 
       
 
Press Release
   
 
Second quarter 2007 results – Timing of investor / analyst meeting changed to 14:30 BST / 9:30 EDT

Basingstoke, UK and Philadelphia, US – 19 July 2007– As previously disclosed, Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) will announce second quarter 2007 earnings on Thursday 26 July 2007.

However, due to the number of other companies also reporting results on that day, Shire has decided to change the time of its investor / analyst meeting to 30 minutes later than previously announced.

All other details remain the same.

Results press release will be issued at:
12:00 BST / 07:00 EDT
Investor meeting and conference call time:
14:30 BST / 09:30 EDT

Analyst meeting and conference call:
Matthew Emmens, Chief Executive Officer and Angus Russell, Chief Financial Officer will host the investor and analyst meeting and conference call at 14:30 BST/9:30 EDT. The venue for the meeting will be at the offices of Financial Dynamics, Holborn Gate, 26 Southampton Buildings, London WC2A 1PB.

Please email claire.rowell@fd.com to register to attend the analyst meeting in London.

The details of the conference call are as follows:

UK dial in:
0800 953 0810
US dial in:
1866 789 2220
International dial in:
+44 (0) 1452 560 068
Password/Conf ID:
10176864#
Live Webcast:*
http://gaia.world-television.com/shire/20070726/

Replay:
A replay of the presentation will be available for two weeks by phone and by webcast for one year.  Details are as follows:

UK dial in
0800 953 1533
 

Registered in England 2883758  Registered Office as above

 
US dial in
1866 247 4222
International dial in
+44 (0) 1452 55 00 00
Pin code
10176864#
Webcast replay:*
http://gaia.world-television.com/shire/20070726/
* Email verification is required
 
For further information please contact:

Investor Relations
Souheil Salah (Rest of the World)
+44 1256 894 160
 
Heidi Wunder (North America)
+1 484 595 8970

 
Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases.  The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions.  Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians.  Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website:
www.shire.com.
 
 

 

-----END PRIVACY-ENHANCED MESSAGE-----